NCI, Inc. reports early termination of HSR waiting period for acquisition
NCI, Inc. announced that the U.S. Federal Trade Commission has granted early termination of the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act with respect to the pending acquisition of NCI by private funds managed by an affiliate of H.I.G. Capital at a price of $20.00 per share, net to the seller in cash, without interest, and subject to deduction for any required withholding of taxes. The early termination of the Hart-Scott-Rodino waiting period has satisfied one of the conditions to the closing of the tender offer. The closing of the tender offer remains subject to other conditions, including the tender of shares of NCI common stock representing at least a majority of the voting power of the shares of Class A and Class B common stock outstanding on a fully-diluted basis and other customary conditions. The closing of the transaction is not contingent on financing. Unless the tender offer is extended, the tender offer and any withdrawal rights to which NCI's stockholders may be entitled will expire at 12:00 midnight, New York City time, at the end of the day on Friday, August 11, 2017. Following the acceptance for payment of shares in the tender offer and completion of the transactions contemplated in the merger agreement, NCI will be an indirect wholly owned subsidiary of an affiliate of H.I.G.